Clinical Trials Logo

Developmental Disabilities clinical trials

View clinical trials related to Developmental Disabilities.

Filter by:

NCT ID: NCT00298818 Completed - Epilepsy Clinical Trials

Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation

Start date: August 2002
Phase: Phase 4
Study type: Observational

The purpose of this study is to assess the efficacy and tolerability in "real-world" clinical practice, of adjunctive zonisamide treatment in adult patients with developmental disabilities and epilepsy.

NCT ID: NCT00261508 Completed - Autistic Disorder Clinical Trials

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)

Start date: August 1999
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the effectiveness of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral symptoms in children with Pervasive Developmental Disorders (PDD).

NCT ID: NCT00251303 Completed - Clinical trials for Autism Spectrum Disorder

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

Start date: August 2005
Phase: Phase 2
Study type: Interventional

This study will examine the effectiveness of riluzole for treating Obsessive-Compulsive Disorder in Youth, Including those with Autism Spectrum Disorders.

NCT ID: NCT00246870 Completed - Clinical trials for Succinic Semialdehyde Dehydrogenase Deficiency

PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency

Start date: October 24, 2005
Phase: N/A
Study type: Observational

This study will use brain imaging to map brain cell receptors for a chemical called GABA, a chemical that inhibits the activities of nerve cells. The study includes patients with succinic semialdehyde dehydrogenase deficiency, or SSADH (a disorder in which an enzyme deficiency disrupts GABA metabolism), their parents, and healthy volunteers. SSADH deficiency causes various neurological and neuromuscular problems, including mild to severe mental retardation, delays in the acquisition of skills requiring the coordination of mental and physical activities (psychomotor retardation), delays in language and speech development, and other symptoms. Healthy volunteers 18-55 years of age, patients with SSADH between 5 and 24 years of age, and parents of patients 18-55 years of age may be eligible for this study. Participants undergo magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning as follows: Magnetic resonance imaging MRI uses a magnetic field and radio waves to produce images of body tissues and organs. For this procedure, the subject lies on a table that is moved into the scanner (a narrow metal cylinder surrounded by a magnetic field) wearing earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. Scanning time varies from 20 minutes to 3 hours, with most scans lasting between 45 and 90 minutes. Participants may be asked to lie still for up to 90 minutes at a time. In addition to standard MRI, participants may also have new types of MRI that may detect brain abnormalities when regular MRI is normal, such as diffusion tensor MRI and magnetic resonance spectroscopy. There are no noticeable differences from ordinary MRI scans. Positron Emission Tomography A catheter (plastic tube) is placed in a vein in the subject's wrist. The subject lies on a table with his or her head placed in the scanner. A mask, used to help keep the head still in the scanner, is placed over the head. The mask is not uncomfortable and has holes for the subject to see through. A radioactive compound called flumazenil is injected into a vein. The scan takes about 90 minutes. Some children need to be sedated for PET or MRI scans. In these cases, chloral hydrate, a standard drug for pediatric diagnostic procedures, is used.

NCT ID: NCT00234247 Completed - Lung Diseases Clinical Trials

Prolonged Outcomes After Nitric Oxide (PrONOx)

Start date: December 2002
Phase: Phase 3
Study type: Observational

The purpose of this study is to look at the long term consequences of prematurity in infants treated with inhaled nitric oxide (iNO) while in the neonatal intensive care unit.

NCT ID: NCT00207935 Completed - Epilepsy Clinical Trials

Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population

Start date: August 2005
Phase: Phase 4
Study type: Interventional

This study is being done to see if children with learning problems can learn how to swallow pills without chewing them. The reason this is important is that if a person has seizures, medications must be taken every day. Most medications need to be taken 2 or 3 times per day. Some medications have slow release and only are taaken once per day. Medications with slow release usually come in capsule form and cannot be opened or chewed. This study investiates whether children with developmental delay can be taught how to swalow pills.

NCT ID: NCT00198055 Completed - Clinical trials for Pervasive Developmental Disorder

A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment for individuals with Asperger's Disorder and Pervasive Developmental Disorder. This is an open-label investigation of aripiprazole in the management of the maladaptive behaviors of autistic disorder. We hypothesize that aripiprazole will be effective for reducing aggression and repetitive behavior.

NCT ID: NCT00166595 Completed - Clinical trials for Child Development Disorders, Pervasive

Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)

Start date: February 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if the known differences in genes influence drug metabolizing enzymes and receptors that are involved in risperidone drug action. The study will determine if differences in these genes will change the concentration of risperidone in the blood over time in children in relation to side effects and clinical response to risperidone.

NCT ID: NCT00161135 Completed - Autism Clinical Trials

Magnetic Resonance Imaging in Children and Adolescents With Autism and Multiple Complex Developmental Disorders

Start date: January 1999
Phase: N/A
Study type: Observational

This study aims to investigate the overlap and differences between autism and MCDD as neuropsychiatric childhood disorders. MRI scans are acquired from subjects with autism, subjects with a diagnosis of MCDD and typically developing controls. Volumetric measure of various brain regions are compared between groups. We hypothesize that subjects with autism will have larger brains than controls, whereas subjects with MCDD will have smaller brains.

NCT ID: NCT00156221 Completed - Autism Clinical Trials

MR Scanning of Very Young Children With Severe Developmental Disorders

Start date: September 2000
Phase: N/A
Study type: Observational

The specific is to study the MR morphologic and spectroscopic brain correlates and predictors of development in children with severe developmental disorders (autistic spectrum disorders and/or mental retardation and/or language disorders). Given the frequently observed association of autism with known medical conditions, particularly in cases with comorbid mental retardation and in cases with atypical autism (Rutter et al., 1994; Gillberg, 1995), children with suspected autism or related developmental disorders will be asked to participate in an extensive state of the art laboratory work-up which includes T1 and T2 weighted MRI of the brain. MRI data will be analyzed both qualitatively, looking for focal abnormalities and degree of myelination, and quantitatively, measuring volumes of total brain, cerebellum, ventricles and grey and white matter. For research purposes, the work-up will be supplied with proton Magnetic Resonance Spectroscopy (MRS) of the brain. This data set provides the opportunity to chart brain-behavior relationships in young children with suspected autism and related PDD cross-sectionally.